Fig. 3

PLK2 overexpression reduces the malignancy of GBM cells both in vitro and in vivo. a, Representative images of immunofluorescence showing the transduction efficiency of U87 and U251 cell lines after lentiviral PLK2 transduction. b, qRT-PCR analysis for measuring the mRNA expression of PLK2 in U87 and U251 cells after lentiviral PLK2 transduction (**P < .001, with student’s t-test). c, Western blot analysis for detecting the PLK2 protein expression in U87 glioma cell line transduced with lentiviral PLK2, lentiviral vector and blank control. β-actin was used as an internal control. d, Time survival curve of U87 cell line transduced with lentiviral PLK2 and negative control (***P < .001, with one-way ANOVA followed by Dunnett’s post-test). e and f, the colony formation ability of U87 cells pre-treated with either lentiviral vector or PLK2 (***P < .001, with student t-test). g, Flow cytometry analyses using Annexin V and Propidium Iodide for apoptotic ratio analysis in U87 cells pretreated with indicated interventions. h and i the migratory ability of U87 cells pre-treated with either lentiviral vector or PLK2. j, Representative images of H&E-stained mouse brain sections after the intracranial transplantation of indicated U87 cell lines. Scale bars: 3 mm H, Kaplan-Meier curve comparing the overall survival of xenograft mice with U87 cells pre-treated with either lentiviral vector or PLK2 (P = 0.0256, with log-rank test). All data were presented as the mean ± SD of triplicate independent experiments